Search research articles
Contact Us
Filters
Showing results (101-110 of 124) with videos related to
Page
of 13
Sort By:
Rheumatology (Oxford, England)
|
July 1, 2026
Progression from oligoarticular to polyarticular psoriatic arthritis and apremilast as a disease modifier: novel insights from FOREMOST
Laura C Coates, Dafna D Gladman, Joseph F Merola, et al.
American Journal of Clinical Dermatology
|
February 8, 2026
Expert Recommendations for the Diagnosis and Management of Chronic Hand Eczema in the United States
Jonathan I Silverberg, David Cohen, Emma Guttman-Yassky, et al.
Journal of Drugs in Dermatology : JDD
|
August 2, 2024
Benefits Over Five Years of Ixekizumab Treatment in Patients With Psoriasis Involving Challenging Body Areas
Alice B Gottlieb, April Armstrong, Andrew Blauvelt, et al.
Lancet (London, England)
|
February 7, 2021
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial
Kristian Reich, Kim A Papp, Andrew Blauvelt, et al.
Dermatology and Therapy
|
December 20, 2025
Short-Term Efficacy of Lebrikizumab Versus Dupilumab in Combination with Topical Corticosteroids in Adults with Moderate-to-Severe Atopic Dermatitis: Matching-Adjusted Indirect Comparison
Raj Chovatiya, April Armstrong, Leon Kircik, et al.
Journal of Psoriasis and Psoriatic Arthritis
|
September 19, 2024
Factors Associated with Multi-Biologic Use in Psoriasis Patients at an Academic Medical Center and Review of Biologic Survival
Edward Hadeler, Sugandh Kumar, Samuel Yeroushalmi, et al.
Journal of Drugs in Dermatology : JDD
|
June 4, 2025
Rapid Onset of Itch Relief With Tapinarof in Two Phase 3 Trials in Atopic Dermatitis
Eric L Simpson, Jonathan I Silverberg, Robert Bissonnette, et al.
The Journal of Dermatological Treatment
|
June 11, 2019
Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2
Michael J Cork, Laurent Eckert, Eric L Simpson, et al.
Dermatology and Therapy
|
November 22, 2019
Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure
April Armstrong, Carle Paul, Luis Puig, et al.
Journal of Drugs in Dermatology : JDD
|
August 10, 2022
International Dermatology Outcome Measures (IDEOM): Report from the 2021 Annual Meeting
Caterina Zagona-Prizio, Jenna Yousif, Carly Grant, et al.
Page
of 13
Search research articles
Search
Showing results (101-110 of 124) with videos related to
Sort By:
Page
of 13
Rheumatology (Oxford, England)
|
July 1, 2026
Progression from oligoarticular to polyarticular psoriatic arthritis and apremilast as a disease modifier: novel insights from FOREMOST
Laura C Coates, Dafna D Gladman, Joseph F Merola, et al.
American Journal of Clinical Dermatology
|
February 8, 2026
Expert Recommendations for the Diagnosis and Management of Chronic Hand Eczema in the United States
Jonathan I Silverberg, David Cohen, Emma Guttman-Yassky, et al.
Journal of Drugs in Dermatology : JDD
|
August 2, 2024
Benefits Over Five Years of Ixekizumab Treatment in Patients With Psoriasis Involving Challenging Body Areas
Alice B Gottlieb, April Armstrong, Andrew Blauvelt, et al.
Lancet (London, England)
|
February 7, 2021
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial
Kristian Reich, Kim A Papp, Andrew Blauvelt, et al.
Dermatology and Therapy
|
December 20, 2025
Short-Term Efficacy of Lebrikizumab Versus Dupilumab in Combination with Topical Corticosteroids in Adults with Moderate-to-Severe Atopic Dermatitis: Matching-Adjusted Indirect Comparison
Raj Chovatiya, April Armstrong, Leon Kircik, et al.
Journal of Psoriasis and Psoriatic Arthritis
|
September 19, 2024
Factors Associated with Multi-Biologic Use in Psoriasis Patients at an Academic Medical Center and Review of Biologic Survival
Edward Hadeler, Sugandh Kumar, Samuel Yeroushalmi, et al.
Journal of Drugs in Dermatology : JDD
|
June 4, 2025
Rapid Onset of Itch Relief With Tapinarof in Two Phase 3 Trials in Atopic Dermatitis
Eric L Simpson, Jonathan I Silverberg, Robert Bissonnette, et al.
The Journal of Dermatological Treatment
|
June 11, 2019
Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2
Michael J Cork, Laurent Eckert, Eric L Simpson, et al.
Dermatology and Therapy
|
November 22, 2019
Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure
April Armstrong, Carle Paul, Luis Puig, et al.
Journal of Drugs in Dermatology : JDD
|
August 10, 2022
International Dermatology Outcome Measures (IDEOM): Report from the 2021 Annual Meeting
Caterina Zagona-Prizio, Jenna Yousif, Carly Grant, et al.
Page
of 13